glp 1 drugs news GLP-1 Medications for Weight Loss: Semaglutide vs Tirzepatide vs Retat – Revolution Health & Wellness The GLP-1 Revolution: From Diabetes

Description

J Clin Invest

We see Novo Nordisk and Eli Lilly as overvalued despite assuming that a quarter of US adults with obesity will be on GLP-1 therapies by 2031, leading to a GLP-1 market north of $200 billion in 2031, before generic semaglutide (Wegovy/Ozempic/Rybelsus) launches. Competition rises

But few grasped the peptide's potential (Furness)

Batch-by-Batch Protection TruShield requires testing for every production batch or lot, ensuring consistent verification rather than one-time product approval

If you have struggled with weight loss and tried different diets with only limited success you might be wondering if a GLP-1 agonist such as Semaglutide (Wegovy/Ozempic) or Tirzepatide (Zepbound/Mounjaro) could be right for you